Pomerantz Law Firm Investigates NovoCure Following Disappointing Trial Results
The Pomerantz Law Firm is investigating potential securities fraud or unlawful business practices by NovoCure Limited (NASDAQ: NVCR) following the release of disappointing Phase 3 trial results. The company's stock price dropped significantly after announcing that its Early Start Arm did not show a statistically significant improvement in overall survival compared to the Maintenance Start Arm.
Tickers: $NVCR
Topics: clinical trial results securities fraud stock price drop